Burton E, Prados M
University of California, San Francisco, Department of Neurosurgery, USA.
Curr Opin Oncol. 1999 May;11(3):157-61. doi: 10.1097/00001622-199905000-00003.
Chemotherapy remains part of the treatment triad that includes surgery and radiation therapy for the management of malignant gliomas. In recent years there has been an increased understanding of the molecular pathways of malignant transformation. Based on this research, new drugs have been evaluated, with specific cellular targets in mind that can be modified or inhibited. Many of these agents are now being tested in phase I and II clinical trials and have shown some promising results. Clearly, not all patients with malignant gliomas respond equally to chemotherapy. Recent evidence suggests that certain molecular markers may predict chemosensitivity in some tumor types, particularly anaplastic oligodendroglioma. This article reviews recent trends in the use of chemotherapy and clinical trials of new therapies for adults with malignant gliomas.
化疗仍然是治疗恶性胶质瘤三联疗法的一部分，该三联疗法包括手术和放射治疗。近年来，人们对恶性转化的分子途径有了更多的了解。基于这项研究，已经对新药进行了评估，这些新药有特定的细胞靶点，可以被修饰或抑制。其中许多药物目前正在进行I期和II期临床试验，并已显示出一些有前景的结果。显然，并非所有恶性胶质瘤患者对化疗的反应都相同。最近的证据表明，某些分子标志物可能预测某些肿瘤类型的化疗敏感性，特别是间变性少突胶质细胞瘤。本文综述了成人恶性胶质瘤化疗的最新趋势和新疗法的临床试验。
